Takeda Pharmaceutical Company Limited (TAK) News
Track canonical SquawkNews coverage tagged to TAK, Takeda Pharmaceutical Company Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibit
NEWS | Sep 30, 2026, 05:00 AM UTC
H
Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call
Takeda Pharmaceutical Co (NYSE: TAK ) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to
LIVE | Sep 17, 2026, 01:06 PM UTC
M
Takeda's Orzeyful gets Japan approval for narcolepsy type 1
Takeda Pharmaceutical's Orzeyful (oveporexton) is approved in Japan as the first and only medicine to treat the underlying cause of narcolepsy type 1, marking its third major regulatory approval worldwide.
REGULATION | Aug 24, 2026, 10:38 AM UTC
L
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28
Takeda Pharmaceutical Co (NYSE: TAK ) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate.
EARNINGS | Jul 30, 2026, 12:12 PM UTC
L
Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29.
Takeda Pharmaceutical Co (NYSE: TAK ) lowers FY2026 Adj EPS guidance from $3.01 to $2.96 vs $1.57 analyst estimate. Lowers FY2026 sales outlook from $29.585 billion to $29.116 billion vs $28.950 billion estimate.
EARNINGS | Jul 30, 2026, 07:44 AM UTC
L
Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine
Insilico Medicine said Thursday it entered into a strategic collaboration with Takeda Pharmaceutical Co. Ltd. (NYSE: TAK ) to use its proprietary Pharma.AI platform to discover and advance new drug candidates across mult
EQUITY | Jul 02, 2026, 05:38 PM UTC
L
Takeda Pharmaceutical shares are trading higher after the company announced a $600 million AI drug discovery partnership with Insilico Medic
Takeda Pharmaceutical shares are trading higher after the company announced a $600 million AI drug discovery partnership with Insilico Medicine.
EQUITY | Jul 02, 2026, 02:02 PM UTC
L
Insilico Medicine Announced Earlier, AI Drug Discovery Collaboration With Takeda Worth Up To $600M; Insilico To Receive~$60M In Initiation F
Insilico Medicine Announced Earlier, AI Drug Discovery Collaboration With Takeda Worth Up To $600M; Insilico To Receive~$60M In Initiation Fees, Near-Term Payments, Milestones, Eligible For Additional Preclinical, Clinic
EQUITY | Jul 02, 2026, 09:15 AM UTC
M
TAK: Takeda Leans Into AI
Takeda's first female CEO is utilizing AI to shape the biopharma business.
EQUITY | Jun 26, 2026, 03:46 PM UTC
M
Takeda Names Julie Kim CEO
Takeda appoints Julie Kim as Representative Director, President, and CEO as Christophe Weber retires
EQUITY | Jun 24, 2026, 07:48 AM UTC